Open AccessTracking oseltamivir-resistance in New Zealand influenza viruses during a medicine reclassification in 2007, a resistant-virus importation in 2008 and the 2009 pandemic
Author(s) -
Richard J. Hall,
Matthew Peacey,
Jacqui Ralston,
Danielle J de Joux,
Judy Bocacao,
Mackenzie Nicol,
Molly Ziki,
Wendy Gunn,
Jing Wang,
Q Sue Huang
Publication year - 2012
Publication title -
western pacific surveillance response journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.515
H-Index - 16
eISSN - 2094-7313
pISSN - 2094-7321
DOI - 10.5365/wpsar.2012.3.3.002
Subject(s) - oseltamivir , neuraminidase , virology , neuraminidase inhibitor , pandemic , medical microbiology , virus , influenza a virus , biology , medicine , context (archaeology) , human mortality from h5n1 , microbiology and biotechnology , covid-19 , infectious disease (medical specialty) , paleontology , disease
Oseltamivir (Tamiflu®) is an important pharmaceutical intervention against the influenza virus. The importance of surveillance for resistance to oseltamivir has been highlighted by two global events: the emergence of an oseltamivir-resistant seasonal influenza A(H1N1) virus in 2008, and emergence of the influenza A(H1N1)pdm09 virus in 2009. Oseltamivir is a prescription medicine in New Zealand, but more timely access has been provided since 2007 by allowing pharmacies to directly dispense oseltamivir to patients with influenza-like illness.